PT - JOURNAL ARTICLE AU - Bernhard Schermer AU - Francesca Fabretti AU - Maximilian Damagnez AU - Veronica Di Cristanziano AU - Eva Heger AU - Sita Arjune AU - Nathan A. Tanner AU - Thomas Imhof AU - Manuel Koch AU - Alim Ladha AU - Julia Joung AU - Jonathan S. Gootenberg AU - Omar O. Abudayyeh AU - Volker Burst AU - Feng Zhang AU - Florian Klein AU - Thomas Benzing AU - Roman-U. Müller TI - Rapid SARS-CoV-2 testing in primary material based on a novel multiplex LAMP assay AID - 10.1101/2020.06.18.20130377 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.18.20130377 4099 - http://medrxiv.org/content/early/2020/06/22/2020.06.18.20130377.short 4100 - http://medrxiv.org/content/early/2020/06/22/2020.06.18.20130377.full AB - Background Rapid and extensive testing of large parts of the population and specific subgroups is crucial for proper management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and decision-making in times of a pandemic outbreak. However, point-of-care (POC) testing in places such as emergency units, outpatient clinics, airport security points or the entrance of any public building is a major challenge. The need for thermal cycling and nucleic acid isolation hampers the use of standard PCR-based methods for this purpose.Methods To avoid these obstacles, we tested PCR-independent methods for the detection of SARS-CoV-2 RNA from primary material (nasopharyngeal swabs) including loop-mediated isothermal amplification (LAMP) and specific high-sensitivity enzymatic reporter unlocking (SHERLOCK).Results Whilst specificity of standard LAMP assays appears to be satisfactory, sensitivity does not reach the current gold-standard quantitative real-time polymerase chain reaction (qPCR) assays yet. We describe a novel multiplexed LAMP approach and validate its sensitivity on primary samples. This approach allows for fast and reliable identification of infected individuals. Primer optimization and multiplexing helps to increase sensitivity significantly. In addition, we directly compare and combine our novel LAMP assays with SHERLOCK.Conclusion In summary, this approach reveals one-step multiplexed LAMP assays as a prime-option for the development of easy and cheap POC test kits.Competing Interest StatementF.Z., O.O.A., J.S.G., J.J., and A.L. are inventors on patent applications related to SHERLOCK technology filed by the Broad Institute, with the specific aim of ensuring this technology can be made freely, widely, and rapidly available for research and deployment. O.O.A., J.S.G., and F.Z. are co-founders, scientific advisors, and hold equity interests in Sherlock Biosciences, Inc. F.Z. is also a co-founder of Editas Medicine, Beam Therapeutics, Pairwise Plants, and Arbor Biotechnologies. N.A.T. is employed by New England Biolabs, Inc, manufacturer of the LAMP reagents and some additional enzymes described in this manuscript. The remaining authors declare no competing financial interests.Funding StatementBS, VB, RUM und FK are supported by the German Federal Ministry for Education and Research (01KI20184). BS, RUM and TB received funding by the German Research Foundation (CRU329). The authors or their institutions did not receive any payment or services from any other third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethikkommission der Medizinischen Fakultaet der Universitaet zu Koeln (IRB of University of Cologne) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available. All protocols will be provided.COVID-19coronavirus disease-2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2qPCRquantitative real-time polymerase chain reactionUTMuniversal transport mediaPOCpoint-of-careLAMPloop-mediated isothermal amplificationSHERLOCKspecific high-sensitivity enzymatic reporter unlockingRPArecombinase polymerase amplificationCtcycle threshold